Evidence map›Paper›PMID 40955622›Full record

ArticleAmerican journal of hematology2025

Recursive Partitioning to Differentiate Acquired From Inherited Bone Marrow Failure Syndromes.

Eléonore Kaphan, Anouk Walter-Petrich, Lise Larcher, Thierry Leblanc, Benedicte Bruno, Edouard Forcade, Cecile Renard, Arthur Sterin, Michael Loschi, Elodie Lainey and 7 more

Abstract read
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Eléonore KaphanAPHP, Service D'hématologie Greffe, Hôpital Saint-Louis, Paris, France.ORCID 0000-0002-3539-6493
Anouk Walter-PetrichUniversité Paris Cité, INSERM U1153, Team ECSTRRA, Paris, France.
Lise LarcherUniversité Paris Cité, Institut de Recherche Saint-Louis, Inserm UMR 1342, Paris, France.
Thierry LeblancAPHP, Hôpital Robert Debré, Service D'hématologie et Immunologie pédiatrique, Paris, France.ORCID 0000-0003-2463-9346
Benedicte BrunoService D'hématologie pédiatrique CHU de Lille, Lille, France.
Edouard ForcadeService D'hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Cecile RenardInstitut D'hématologie et D'oncologie Pédiatrique, Lyon, France.
Arthur SterinService D'hématologie Immunologie Oncologie Pédiatrique, CHU de Marseille, France.
Michael LoschiService D'hématologie Greffe, CHU de Nice, France.
Elodie LaineyService D'hématologie Biologique, Cytométrie de Flux, CHU Robert Debré, Paris, France.ORCID 0000-0002-0224-4338
Jean SoulierUniversité Paris Cité, Institut de Recherche Saint-Louis, Inserm UMR 1342, Paris, France.
Caroline KannengiesserGenetics Laboratory, Bichat Hospital APHP Paris France; Paris Cité University INSERMU1152, Paris, France.
Gérard SociéAPHP, Service D'hématologie Greffe, Hôpital Saint-Louis, Paris, France.
Régis Peffault de LatourAPHP, Service D'hématologie Greffe, Hôpital Saint-Louis, Paris, France.ORCID 0000-0001-6222-4753
Mony FahdAPHP, Hôpital Robert Debré, Service D'hématologie et Immunologie pédiatrique, Paris, France.
Jérome LambertUniversité Paris Cité, INSERM U1153, Team ECSTRRA, Paris, France.
Flore Sicre De FontbruneAPHP, Service D'hématologie Greffe, Hôpital Saint-Louis, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Distinguishing inherited bone marrow failure (IBMF) from acquired aplastic anemia (aAA) at diagnosis is a major clinical challenge and is essential for appropriate treatment and patients' counseling. Genetic testing to exclude IBMF is frequently subject to delays of several months and may not be available in all centers and could not be applied to all patients in a large number of countries. Our study aimed to develop a practical scoring system to identify patients who are unlikely to have IBMF. Patients in the training set (N = 150) were classified as having either aAA or IBMF based on genetic results and/or response to immunosuppressive therapy. We retrospectively recorded 33 clinical and laboratory characteristics at the time of diagnosis. The diagnostic algorithm was then constructed using recursive partitioning. This unbiased model handles missing values using conditional inference procedures. Model sensitivity addresses the ability to correctly predict aAA. Three of the variables of interest were selected by the model in the final algorithm: morphological abnormalities, PNH clone (≥ 0.1% on granulocytes), and acute onset of BMF (cytopenia < 1 year). In the training set, the algorithm achieved a sensitivity of 96.2% (IC95%: 91.4%-98.8%) and a specificity of 88.2% (IC95%: 63.6-98.5) in differentiating aAA from IBMF. We then applied this algorithm to a validation set of 465 patients (aAA n = 368 (79.1%); IBMF n = 97 (20.9%)) and obtained similar sensitivity of 95.7% (IC95: 93-97.5) and specificity of 91.8% (IC95%: 84.4-96.4) with a positive predictive value of 97.8% (IC95%: 95.7-99). This efficient and practical scoring system might help physicians to identify patients who do not need genetic screening, allowing prompt start of treatment. Positive predictive value may be improved in specific populations by adding telomere length, AFP and HbF values.

Indexed as

AlgorithmsAnemia, AplasticHemoglobinuria, ParoxysmalAdolescentAdultAgedBone Marrow DiseasesBone Marrow Failure DisordersChildChild, PreschoolDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRetrospective Studiesaplastic anemiainherited bone marrow failurePNH

Identifiers

PMID40955622
PMCPMC12516657

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.